COMPANY UPDATES
August 13, 2020
We are excited to collaborate with The Estée Lauder Companies in a joint development agreement to discover senomodulators! >>
November 16, 2020
Atropos is one of the companies selected for Nature Biotechnology’s new article on senolytics. Read more >>
June 11, 2020
Initial round of high throughput screening with Scripps Research Institute is completed and senosuppressor hits are currently being evaluated at Atropos.
April 29, 2020
Atropos is pleased to announce the capital support from Incite and LC Global Partners helping us to pursue our goals to identify senomodulators.
Atropos Founder is interviewed by James Ruhle on The Simple Biotech Podcast. Andy talks about aging, Atropos, and provides an analogy to COVID-19. Many thanks to James for hosting. >>
March 17, 2020
Atropos is pleased to announce the recruitment of two individuals, Ethan Than MBA and Harsha Agarwal PhD, to our Business Development and Laboratory efforts. >>
Atropos is pleased to announce the recent submission of our non-provisional patent by WSGR describing the FATES platform for identification of senomodulators.
February 26, 2020
Atropos welcomes William D. Tap to the Board of Directors. Bill is the Chief of the Sarcoma Medical Oncology Service at Memorial Sloan Kettering Cancer Center. He has experience in translational medicine and drug development. >>
September 11, 2019
Atomwise and Atropos Launch Joint Venture to Discover Senescence Modulating Small Molecules for Cancer Patients >>
January 13, 2019
Atropos Selected as Finalist to Present in RESI San Francisco 2019 West Coast Pitch Challenge >>
